Aminoglycoside use and intensive care unit-acquired weakness: A systematic review and meta-analysis

The relationship between aminoglycoside use and intensive care unit (ICU)-acquired weakness remains controversial. In the present study, we performed a systematic review and meta-analysis to examine the relationship between aminoglycoside use and ICU-acquired weakness in critically ill patients. The...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020, Vol.15 (3), p.e0230181-e0230181
Main Authors: Yang, Tao, Li, Zhi-Qiang, Li, Hong-Liang, Zhou, Jian-Xin, Chen, Guang-Qiang
Format: Article
Language:English
Subjects:
Aminoglycosides
Bias
Biology and Life Sciences
Chi-square test
Clinical trials
Cohort analysis
Critical care
Electrophysiology
Evaluation
Guillain-Barre syndrome
Health risks
Heterogeneity
Histopathology
Hospitals
Intensive care
Medical research
Medicine
Medicine and Health Sciences
Meta-analysis
Mortality
Nursing
Physical Sciences
Research and Analysis Methods
Sensitivity analysis
Statistical analysis
Statistical tests
Studies
Subgroups
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The relationship between aminoglycoside use and intensive care unit (ICU)-acquired weakness remains controversial. In the present study, we performed a systematic review and meta-analysis to examine the relationship between aminoglycoside use and ICU-acquired weakness in critically ill patients. The PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials and Cumulative Index of Nursing and Allied Health Literature databases were searched from the earliest available date to July 10, 2019. Randomized controlled trials and prospective cohort studies examining the relationship between aminoglycosides and ICU-acquired weakness in adult ICU patients were included. Two authors independently screened titles/abstracts, reviewed full text and extracted data from the included studies. We performed the Meta-analysis using Stata version 15.0 and used the DerSimonian-Laird random effects model for data analyses. Heterogeneity was evaluated using the χ2 statistic and I2 statistic. Publication bias was evaluated with funnel plots qualitatively, the Begg's test and Egger's test quantitatively. Ten prospective cohort studies were included and analysed in this review. The overall effect sizes of the studies revealed a statistically significant relationship between aminoglycoside use and ICU-acquired weakness (OR, 2.06; 95%CI, 1.33-3.21; I2 = 56%). Subgroup and sensitivity analyses suggested a significant association between aminoglycoside use and studies limited to patients with clinical weakness (OR, 2.74; 95%CI, 1.83-4.10; I2 = 0%), and not to studies limited to patients with abnormal electrophysiology (OR, 1.78; 95%CI, 0.94-3.39; I2 = 59%), a large sample size (OR, 1.81; 95%CI, 0.97-3.39; I2 = 75%), or low risk of bias (OR, 1.59; 95%CI, 0.97-2.60; I2 = 56%); however, statistical heterogeneity was obvious. There were no significant publication biases found in the review. The review revealed a significant relationship between aminoglycoside use and ICU-acquired weakness.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0230181